USB — U.S. Bancorp

The tape says bearish even though the sell side does not. As of 2026-10-15 the stock was down 9.49% over one month and 12.02% over three months, below all three key moving averages and at an RSI(14) of 32.45 - near-oversold territory. Yet the analyst community is constructive: consensus rating 'Buy'/'Moderate Buy', consensus target $69.94 (12 analysts, low $64, high $76), with 24 buys and 22 holds. The gap is a macro/credit debate, not an earnings debate: Q3 EPS beat, net income grew 10% YoY, guidance was raised, and CET1 of 10.8% is comfortably above requirements - but the provision for credit losses jumped to $654M from $538M sequentially, deposit betas and the rate path threaten the 2.80% NIM, and JPMorgan trimmed its target to $65 with a neutral stance. The market is discounting a credit and margin normalization that has not yet shown up in reported results, which is exactly why price and earnings momentum are pointing in opposite directions.

The three-year arc is a clean recovery-and-expansion story, with a flattening at the very end. Operating income on the reported FMP series went from $1.00B in Q4 2023 (a quarter distorted by one-off charges including the FDIC special assessment) to $1.67B, $2.06B, $2.07B and $2.11B across 2024, then to $2.16B, $2.29B, $2.53B, $2.53B across 2025, and $2.69B, $2.72B, $2.80B in Q1-Q3 2026. On that basis operating margin expanded from 9.6% in Q4 2023 to 24.9% in Q3 2026 - roughly 1.9pp of expansion in the last twelve months alone, consistent with management's ~300bps positive operating leverage guidance in Q3 2026. Diluted EPS compounded in a near-straight line from $0.49 (Q4 2023) to $1.34 (Q3 2026), with a single down-sequential blip in Q1 2026 ($1.18 vs $1.26 in Q4 2025, seasonal plus provision build), then $1.35 and $1.34 in Q2/Q3 2026 - so YoY growth is intact (+10% net income YoY in Q3 2026) but sequential momentum has flattened for two quarters. One data caveat worth flagging honestly: FMP's gross revenue line ($11.25B in Q3 2026) grew only ~2.3% YoY, while company-reported total net revenue was $7.97B, +8.7% YoY - these are different bases and not comparable, so I weight the company-reported figures, the margin progression, and EPS, which all agree on steady improvement. The judgment: this is a maturing uptrend, not a broken one, and not a cyclical trough - USB is past the 2023-24 earnings trough and now in the 'prove the operating leverage' phase.

Modestly cheap to fair, with a positive skew. As of 2026-10-15, USB traded at 10.99x trailing EPS of $5.375, versus its own 5-year average P/E of 12.04x - roughly a 9% discount to its own history - and at 10.8x the next-FY consensus EPS of $5.239. PEG is 0.632, price/sales of 2.169 sits below the 5-year average of 2.24, and price/book of 1.32 against an 11.6% ROE is roughly the 'justified' P/B implied by a 10% cost of equity and ~5-6% growth. The 3.636% dividend yield is a real, cash-backed component of return (payout ~39% of forward EPS). The deterministic model's own overlay calls this 'Neutral vs. its own history' (score 57.4). Nothing here is expensive; the discount exists because USB earns a lower ROTCE than JPMorgan or Wells Fargo and because credit costs are normalizing upward. At ~10.8x forward with mid-single-digit EPS growth plus a 3.6% yield, you are being paid to wait.

This is the crux of the USB setup as of 2026-10-15. Earnings are going up while the stock goes down: EPS +10% YoY, guidance raised to 8-9% FY26 revenue growth, +300bps operating leverage targeted, and yet the shares are 12% lower over three months. That divergence means the market is pricing a future that reported numbers have not yet shown - faster/deeper rate cuts compressing NIM below 2.80%, deposit beta pressure, or a credit cycle that turns the $538M-to-$654M QoQ provision step-up into a trend rather than noise. The playbook: as long as the net charge-off ratio stays near 0.51% and NII delivers the guided +4-6% YoY in Q4, the earnings/price gap should close in the shareholder's favor. If provisions make another ~20% sequential jump and NCOs push materially higher, then today's 'cheap' 10.8x forward P/E is a value trap because the denominator is about to be revised down. Watch two lines above all others on 2027-01-20: net interest income guidance and the provision.

Technically weak but approaching a value-friendly zone, as of 2026-10-15. RSI(14) stood at 32.45 - near oversold but not yet below the classic 30 threshold. Price of $56.40 was -2.69% versus the 20-day SMA, -7.54% versus the 50-day SMA and -2.53% versus the 200-day SMA, which mathematically puts the 20-day near $57.96, the 200-day near $57.86 and the 50-day up at roughly $61.00. The pattern is a stock that ground sideways through the summer, failed at the low-$60s, and broke down over the last six to eight weeks, leaving price pinned just under a converged 20-/200-day and no confirmation of a bottom. Returns of -1.25% (1wk), -9.49% (1mo), -12.02% (3mo) but +1.51% (6mo) frame it as a sharp recent derating rather than a long-term downtrend. Entry-timing implication: for a long-term holder the risk/reward has improved, but there is no technical all-clear - a reclaim of the 200-day (~$57.9) and then the 50-day (~$61) with RSI back above 45 would be the first evidence the sellers are done. Note these figures pre-date the market's full reaction to the same-day Q3 print.

• Rate path and deposit betas: NIM printed 2.80% in Q3 2026 with Q4 NII guided +4-6% YoY, so the market's fear of aggressive cuts compressing asset yields faster than funding costs is the single biggest swing factor for the earnings estimate.
• Credit normalization: provision for credit losses rose to $654M from $538M sequentially with a 0.51% net charge-off ratio - commercial real estate, small-business and card delinquencies are the swing items in a softening economy.
• Regulatory capital and Basel III endgame / stress capital buffer: CET1 of 10.8% as of 2026-09-30 leaves room for buybacks and dividends, but any tightening of loss-absorption buffers directly caps ROTCE and capital return.
• Regional-bank sector rotation and deposit competition: USB's scale (~$703B assets) and fee engines (Elavon merchant acquiring, trust, capital markets) differentiate it, but sector-wide funding-cost and sentiment swings still drive the multiple.
• Capital-markets and payments cycle: capital markets revenue surged 69.3% YoY aided by a full quarter of BTIG, tying part of USB's fee growth to deal activity and volatility; the blockchain/stablecoin (USBDC on Stellar) cross-border pilot adds longer-dated optionality.

• Q4 2026 results (estimated 2027-01-20): the guided +4-6% YoY NII, the ~300bps positive operating leverage target, and whether the provision stabilizes or steps up again.
• BTIG integration scaling capital markets revenue beyond the +69.3% YoY recorded in Q3 2026.
• Further NIM expansion as deposit costs reprice and the 2.80% Q3 2026 level proves a floor rather than a peak.
• Capital return acceleration: CET1 of 10.8% versus requirements gives room for larger buybacks to compound book value per share.
• Easing of regional-bank credit fears; a sector re-rating would compress the current ~9% discount to USB's own 5-year average P/E of 12.04x.

• Credit deterioration: provisions up 21.6% sequentially to $654M in Q3 2026 - another two quarters of that pace would start cutting consensus EPS and make today's 10.8x forward P/E look less cheap.
• NIM compression if rate cuts outpace deposit repricing, or if deposit competition forces higher funding costs and offsets the guided +4-6% Q4 NII growth.
• Failure to deliver the ~300bps operating leverage target, given ongoing technology spend and BTIG integration costs (noninterest expense is the lever management most controls).
• Structural profitability gap: 11.6% ROE and 4.5% ROIC are below top-tier peers, which is why USB has historically carried a valuation discount and may not fully close even if earnings beat.
• Regulatory capital tightening (Basel III endgame / stress buffer) that consumes excess capital and prevents the buyback that would otherwise lift EPS growth above the ~2-5% consensus path.

Yes, this is a reasonable place to own U.S. Bancorp for an income-plus-modest-growth investor, but it is a value-and-carry argument, not a momentum one. As of 2026-10-15 you are buying a scale-advantaged top-10 U.S. bank at 10.8x forward EPS against a 12.04x own-history average, 1.32x book, and a 3.64% dividend, while the underlying trajectory is improving - Q3 2026 EPS of $1.34 beat, net income +10% YoY, revenue guidance raised to 8-9%, CET1 at 10.8%. The bear case is entirely about the next provision print and the rate path, not about anything broken in the franchise. My fair-value work puts the shares around $62 (+10%) plus the dividend, so the skew is positive but not dramatic, and the 12% three-month drawdown means you may sit through more mark-to-market pain before the earnings and the price re-sync. Size it as a core financial holding, not a conviction table-pounder.

I applied 11.8x to next-FY consensus EPS of $5.239 (a slight discount to USB's own 5-year average P/E of 12.04x to reflect below-peer ROTCE and rising provisions, but a premium to the 10.8x forward multiple the market is currently paying), which yields about $61.8; cross-checking with the justified P/B formula (ROE 12.0%, sustainable growth 5.5%, cost of equity 9.75% -> ~1.45x book) against book value per share of $42.63 (equity of $66.425B / ~1.558B shares) yields about $61.8 as well, so I set fair value at $62.00 - roughly +10% price upside from the 2026-10-15 close of $56.40, before the 3.64% dividend.